Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$101.37M-42.7%$113.03M-44.5%$121.05M-52.1%$131.4M-47.8%$176.77M-19.0%
$22.98M-81.5%$23.3M-81.8%$34.38M-71.1%$37.01M-68.9%$123.96M+276%
$124.35M-58.6%$136.33M-58.9%$155.43M-58.2%$168.42M-54.6%$300.72M+19.8%
-$123.05M+59.1%-$135.03M+59.3%-$154.03M+58.3%-$167.02M+54.7%-$300.52M-20.6%
$13.02M+61.7%$12.2M-9.6%$9.01M-58.5%$5.83M-80.5%$8.05M-75.2%
-$7.13M-100%-$5.03M-100%-$1.05M-100%$3.32M-99.8%$2.02B+10,099%
-$130.18M-107%-$140.05M-108%-$107.22M-107%-$115.83M-107%$1.77B+757%
$2K0.0%$2K0.0%$2K$2K$2K
-$130.19M-107%-$140.06M-108%-$107.22M-107%-$115.83M-107%$1.77B+753%
-$8.39-107%-$9.04-108%-$6.93-106%-$7.49-107%$119.84+651%
-$120.71M+59.5%-$132.54M+59.7%-$151.42M+58.8%-$164.23M+55.3%-$297.93M-20.1%
-$123.05M+59.1%-$135.03M+59.3%-$154.03M+58.3%-$167.02M+54.7%-$300.52M-20.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Inhibrx Biosciences, Inc.'s revenue?
Inhibrx Biosciences, Inc. (INBX) generated $1.3M in revenue over the trailing twelve months, up 550.0% year over year.
Is Inhibrx Biosciences, Inc. profitable?
Inhibrx Biosciences, Inc. is not currently profitable: it reported a net loss of $130.2M over the trailing twelve months, a -10773.5% net margin.
What is Inhibrx Biosciences, Inc.'s earnings per share?
Inhibrx Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-8.39.
Where does Inhibrx Biosciences, Inc.'s income statement data come from?
Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.